Converge Bio, an innovative startup specializing in AI-driven drug discovery, has successfully secured $25 million in a Series A funding round. The investment was spearheaded by Bessemer Venture Partners, with significant contributions from high-ranking executives at renowned companies including Meta, OpenAI, and Wiz. This funding will bolster Converge Bio's efforts to revolutionize the pharmaceutical industry through cutting-edge artificial intelligence technologies. With a strong backing from industry leaders, the startup is well-positioned to advance its mission of accelerating drug development and improving healthcare outcomes.